Interleukin 13 mediates the modulatory effects of monocytes on LNCaP human prostate cancer cells
1998

Monocytes and Prostate Cancer Cells: The Role of Interleukin 13

Sample size: 3 publication Evidence: moderate

Author Information

Author(s): Z Culig, A Hobisch, M Herold, A Hittmair, M Thumher, IE Eder, MV Cronauer, C Rieser, R Ramoner, G Bartsch, H Klocker, G Konwalinka

Primary Institution: University of Innsbruck

Hypothesis

Do peripheral blood monocytes influence the growth and secretion in androgen-responsive prostate cancer cells?

Conclusion

Monocyte-derived interleukin 13 inhibits the proliferation of androgen-responsive prostate tumor cells and reduces androgen receptor and prostate-specific antigen levels.

Supporting Evidence

  • Conditioned medium from monocytes reduced proliferation in a dose-dependent manner.
  • AR protein decreased by 70% and PSA levels were reduced by approximately 80% after treatment with MCM.
  • The effects of MCM were abolished by pretreatment with a neutralizing anti-IL-13 antibody.

Takeaway

Monocytes can help slow down prostate cancer cells by releasing a substance called interleukin 13, which makes the cancer cells grow less and produce less of a specific protein.

Methodology

LNCaP cells were treated with monocyte-conditioned medium to assess proliferation and secretion of prostate-specific antigen.

Limitations

The study was limited to in vitro experiments and did not explore in vivo effects.

Participant Demographics

Healthy volunteers provided peripheral blood for monocyte extraction.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication